Back to Search
Start Over
Bayer to present results from phase III OASIS 1 and 2 of elinzanetant to treat vasomotor symptoms associated with menopause at ACOG meeting
- Source :
- PharmaBiz. May 10, 2024
- Publication Year :
- 2024
-
Abstract
- Bayer will present detailed results from the pivotal phase III studies OASIS 1 and 2 evaluating the efficacy and safety of the investigational compound elinzanetant versus placebo, at the upcoming [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- PharmaBiz
- Publication Type :
- Periodical
- Accession number :
- edsgcl.793359532